MARSEILLE, France, September 04, 2007 – IPSOGEN, a leading molecular diagnostic company based in France and Connecticut, today announced that it has signed an agreement with DNAVision, a leading provider of pharmacogenomic services in Europe. With this agreement, IPSOGEN gains the capability to offer its portfolio of breast cancer profiling tests to institutions and patients in a CLIA/ISO17025 certified environment.
“This agreement with DNAVision, a recognized provider of high quality pharmacogenomic tests enables IPSOGEN to launch a new generation of IVD profiling diagnostic products addressing unmet needs in guiding breast cancer therapies” said Vincent Fert, president and CEO of IPSOGEN. “DNAVision microarray testing facilities have the most advanced quality standards in Europe. IPSOGEN can now offer its microarray profiling services at the level of quality of quantitative PCR, the industry gold standard. This agreement definitely positions IPSOGEN as a technology leader in diagnostic gene profiling” added Jean-Marc Le Doussal, IPSOGEN Director of Breast Cancer Program.
“We are delighted to combine our quality gene expression services with the genomic signatures discovered and validated by IPSOGEN. With this agreement, we enter in a new era where microarrays are used as diagnostic tools” said Jean-Pol Detiffe, CEO of DNAVision. “This agreement is a new evidence that DNAVision becomes the technical partner of choice for biotech companies who want to step into the diagnostic market without facing long IVD application procedures but with the help a quality certified service provider generating data available for clinical and diagnostic purposes.” added Michael Herman, DNAVision, Business Development Director.
Ipsogen has developed in collaboration with leading academic institutions expert in cancer care a range of microarray-based genomic signatures to characterize tumors and guide treatment options in breast cancer.
About IPSOGEN
IPSOGEN is a molecular diagnostic company focused on the development and commercialization of innovative diagnostic products to guide treatment options in cancers. IPSOGEN has built a comprehensive portfolio of unique products in blood cancers available in more than 50 countries all over the world to leading institutions involved in cancer care. IPSOGEN products are registered as IVD in Europe.
Leveraging its expertise in blood cancers, IPSOGEN has developed, in partnership with leading cancer institutions, a pipeline of diagnostic products in breast cancer.
IPSOGEN is headquartered in Marseille, France, and has its U.S. offices in New Haven, Connecticut. For more information about IPSOGEN, please visit www.ipsogen.com.
About DNAVISION
DNAVision is a leading provider of applied pharmacogenetic & pharmacogenomic services.
DNAVision offers the powerful combination of different technologies in expression profiling, SNP genotyping and sequencing in a high quality environment (First European laboratory to be ISO17025 accredited). DNAVision is a spin-off of University of Brussels and Institute of Pathology and Genetics. More information on DNAVision’s service portfolio can be found on www.dnavision.be.
Forward-looking Statements
All statements in this press release that are not historical are “forward-looking statements”, including statements regarding Ipsogen “expectations,” “beliefs,” “hopes,” “intentions,” “strategies” or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to: risks and uncertainties associated with the agreement discussed in this press release; risks of the company’s ability to achieve and sustain higher levels of revenue, higher gross margins and reduced operating expenses; uncertainties relating to technological approaches, manufacturing and product development; personnel retention; uncertainties related to cost and pricing of products; dependence on collaborative partners; uncertainties relating to sole-source suppliers; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation.
NOTE: Ipsogen and the Ipsogen Logo are registered trademarks owned by Ipsogen. DNAVision and the DNAVision Logo are registered trademarks owned by DNAVision.
IPSOGEN Contact: Vincent Fert President and CEO +33(0) 4 91 29 30 90
DNAVISION Contact : Jean-Pol Detiffe CEO +32(0)71378527
